A recent BBC investigation into banned muscle-building drugs, selective androgen receptor modulators (Sarms), highlights the need for a clearer and more dynamic novel foods regime. The Food Standards Agency (FSA) has commissioned a report that proposes the complete dismantling of the current system, among other models. As the lines between food, medicine, and technology become increasingly blurred, it remains to be seen whether the FSA can demonstrate the “art of the possible” in improving the Novel Foods Regulatory Framework.
Sarms have been categorized by the FSA as unauthorised novel foods due to concerns over their adverse side effects. Despite restrictions, they are openly sold online, in shops, and in gyms throughout the UK. The BBC investigation reveals a lack of understanding among potential consumers and evidence that suppliers are misleading users about the risks of Sarms.
This situation is reminiscent of the UK’s CBD industry, which also faced regulatory challenges. CBD products, marketed as food supplements, gained popularity after the 2018 change in legislation that allowed easier access to medicinal cannabis products. While Sarms have a narrower appeal, CBD products have a broader range of consumer applications and have shown fewer harmful side effects.
The origins of these products differ as well. CBD is a naturally occurring cannabinoid found in the cannabis plant, with a long history of consumption for various purposes. On the other hand, Sarms were accidentally created during research into prostate cancer treatment and have since been developed to combat muscle-wasting disease.
Both Sarms and CBD products have been regulated under the same framework, highlighting the lack of clarity and transparency in their regulatory status. The FSA has recognized this issue and invited Deloitte to review the Novel Foods Regulatory Framework. The review proposes alternative regulatory models to address inefficiency and improve transparency.
The proposed options for reforming the regulatory framework cover a wide range of possibilities, from addressing the current pain points to focusing more on consumer awareness of novel food safety. The report aims to demonstrate the potential for sweeping reform, allowing for a more nuanced approach that considers the complexity of products falling under novel food regulations.
Applying the same regulatory approach to both CBD products and Sarms may not be appropriate, as they differ in their characteristics and risks. Taking a more progressive approach and starting from scratch could foster greater engagement with businesses and consumers, leading to potential authorisation of these products.
While the executive summary of the report lacks specifics, it is commendable that the FSA is open to the idea of starting afresh and considering a wide range of alternatives. This demonstrates a progressive mindset in the typically cautious world of regulation.
